Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119713 | 0.88 | MEN1 (0.61) | MEN1KMT2ATDP1LMNAHTT | |
| SCHEMBL118604 | 0.88 | MEN1 (0.54) | MEN1KMT2ATDP1LMNAHTT | |
| SCHEMBL117883 | 0.87 | MEN1 (0.53) | MEN1KMT2ATDP1LMNAHTT | |
| SCHEMBL118688 | 0.85 | FLT1 (0.55) | MEN1KMT2ATDP1LMNAHTT | |
| SCHEMBL120256 | 0.84 | MEN1 (0.54) | MEN1KMT2ATDP1LMNAHTT | |
| SCHEMBL27866035 | 0.83 | MEN1 (1.00) | MEN1KMT2ATDP1LMNAHTT | |
| SCHEMBL121322 | 0.83 | CCR4 (0.47) | MEN1KMT2ATDP1LMNAHTT | |
| SCHEMBL119177 | 0.81 | KMT2A (0.77) | MEN1KMT2ATDP1LMNAHTT | |
| SCHEMBL118273 | 0.81 | KDM1A (0.51) | MEN1KMT2ALMNAGAAALDH1A1 | |
| SCHEMBL119346 | 0.77 | CYP2C9 (0.51) | MEN1KMT2ATDP1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102427810-A | Sulfamoylbenzoic acid derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2424517-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | MEN1 1593/4885KMT2A 941/4885TDP1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.